CRISPR THERAPEUTICS AG

CRSP

CIK 0001674416 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$864K
↓-97.6% -$35Mvs FY2024 (Q4)
Gross Profit
$864K
↓-97.6% -$35Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0ROIC -27.2% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 13.32 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.00x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -97.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -14854.8% · trend +5907.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$914K
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$72M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$2.27B
everything owned
Total liabilities
$343M
everything owed
Stockholders' equity
$1.92B
shareholder claim

Recent performance · 45 quarters

Revenue↓-97.6% -$35M
$864K
Net Income↓-23.9% -$20M
$-106M
Free Cash Flow↓-103.5% -$263K
$-517K
Operating Margin↑+3439.2pts
-14854.8%

Drill down